MNG390
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.621
- INTERFERON_GAMMA_RESPONSE+0.558
- ALLOGRAFT_REJECTION+0.518
- IL6_JAK_STAT3_SIGNALING+0.460
- INFLAMMATORY_RESPONSE+0.439
- TNFA_SIGNALING_VIA_NFKB+0.398
- COMPLEMENT+0.326
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.272
- ANGIOGENESIS+0.257
- MTORC1_SIGNALING+0.237
Top 10 suppressed
- BILE_ACID_METABOLISM-0.187
- ESTROGEN_RESPONSE_EARLY-0.163
- XENOBIOTIC_METABOLISM-0.160
- DNA_REPAIR-0.152
- MYC_TARGETS_V1-0.101
- PEROXISOME-0.085
- SPERMATOGENESIS-0.085
- ANDROGEN_RESPONSE-0.075
- MYOGENESIS-0.063
- CHOLESTEROL_HOMEOSTASIS-0.059
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 19-004D2_Primary | — | — | 0.870 |
| 2 | TCGA-BH-A1F0-01A-11R-A137-07 | — | D | 0.854 |
| 3 | aMVAC.P_008_TURBT_S226 | — | — | 0.846 |
| 4 | TCGA-FD-A62N-01A-11R-A30C-07 | — | — | 0.845 |
| 5 | TCGA-D8-A1JL-01A-11R-A13Q-07 | — | D | 0.839 |
| 6 | SRR8518406 | — | D | 0.833 |
| 7 | SRR35579823 | — | D | 0.830 |
| 8 | TCGA-AR-A1AJ-01A-21R-A12P-07 | — | D | 0.828 |
| 9 | MNG814 | — | — | 0.828 |
| 10 | 20050099.TNBC | — | D | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.621 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.558 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.518 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.439 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.398 | Inavolisib | — uncovered |
| COMPLEMENT | 0.326 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.272 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.257 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.237 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.229 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.228 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.209 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.193 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.186 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.174 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.169 | Inavolisib | — uncovered |
| HYPOXIA | 0.167 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.152 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.144 | Idelalisib | — uncovered |